SR One

Ancora Biotech will use the funding to boost the clinical development of its trio of antibody treatments.

SR One, a biotech venture firm that recently spun out from GlaxoSmithKline, has raised $500 million for its new fund.

UK-based drug developer Pulmocide Ltd has closed $30.4 million in Series B financing. SR One led the round with participation from other investors that included Longwood Fund, SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation - JJDC, Inc. and Touchstone Innovations plc.

Waltham, Massachusetts-based Morphic Therapeutic, a biotechnology company focused on developing oral integrin drugs, has closed $51.5 million in Series A financing. SR One and Pfizer Venture Investments led the round with participation from other investors that included Omega Funds and AbbVie Ventures.

Cambridge, Massachusetts-based Spero Therapeutics, a biopharmaceutical company targeting drug resistant bacterial infections, raised $30 million in Series B preferred financing, matching the $30 million Series A round Spero raised in June. Existing Series A investors Atlas Venture, SR One, MRL Ventures, Lundbeckfond Ventures, The Kraft Group and Partners Innovation Fund all returned to participated.

Cambridge, Massachusetts-based hearing company Decibel Therapeutics has launched with $52 million in Series A funding. Third Rock Ventures LLC led the round with participation from SR One. In addition to the funding, Kevin Starr, chairman and interim CEO of Decibel Therapeutics, Craig Muir, partner and chief technology officer at Third Rock and Dr. Jens Eckstein, president of SR One, have been named to Decibel Therapeutics' board of directors.

Gladius Pharmaceuticals Inc has secured $4.1 million in a Series A financing. The round was led by Canadian venture capital firm Lumira Capital through its Merck Lumira Biosciences Funds. Joining Lumira in the deal was the Fonds de solidarité FTQ and SR One, an affiliate of GlaxoSmithKline. Based in Montréal, Gladius is a biotechnology company focused on developing novel drugs to treat life-threatening, multi-drug-resistant bacterial infections. It is led by CEO Michael Atkin. Lumira's Daniel Hétu said the Gladius technology "is demonstrating strong promise to restore treatment options for resistant Gram-negative infections which have become a global challenge."

Cambridge, Massachusetts-based Spero Therapeutics LLC, a biopharmaceutical company that focuses on treating bacterial infections, has raised $30 million in Series A funding. Lundbeckfond Ventures led the round with participation from other investors that included Merck Research Ventures, The Kraft Group, Atlas Venture, SR One and Partners Innovation Fund. In conjunction with the funding, Lundbeckfond Ventures’s Casper Breum and Merck’s Dr. Josh Resnick have been added to Spero's board.

The stock began trading February 10, 2023 on the NASDAQ under the ticker symbol "MLYS."

Montreal-based protein profiling company Nomic Bio has secured $17 million in Series A financing.

Previously, he worked at Ghost Tree Capital where he was a senior analyst.

San Carlos, California-based Dren Bio Inc, a biotech company, has secured $60 million in Series A funding.

Palleon Pharmaceuticals, a biotech company, has closed $100 million in Series B financing.

Watertown, Massachusetts-based Pandion Therapeutics Inc, a developer of treatments for patients suffering from autoimmune diseases, has raised $135 million for its IPO after pricing its 7.5 million shares at $18 per share.

Tranquis Therapeutics, a private immuno-neurology company, has raised $30 million in Series A funding.

Design Therapeutics, which is developing treatments for serious degenerative disorders, has raised $45 million in Series A funding.